Effects of Omalizumab (Xolair® ) on Airway Hyperresponsiveness

DISCUSSION/CONCLUSIONS: In our study, omalizumab did not affect indirect or direct measures of airway hyperresponsiveness nor FENO, an inflammatory marker, at the end of the therapy. [...]omalizumab's therapeutic benefit may not be due to changes in airway hyperresponsiveness.

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2009-02, Vol.123 (2), p.S263-S263
Main Authors: Patel, B.M, Chiang, D.T., MD, Clark, J.P, Romero, F.A, Casale, T.B
Format: Article
Language:English
Subjects:
Allergy and Immunology
Asthma
Drug therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:DISCUSSION/CONCLUSIONS: In our study, omalizumab did not affect indirect or direct measures of airway hyperresponsiveness nor FENO, an inflammatory marker, at the end of the therapy. [...]omalizumab's therapeutic benefit may not be due to changes in airway hyperresponsiveness.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2008.12.1020